mRNA and cancer

MRNA vaccines and cancer

Article investigates the potential association between modified mRNA (modRNA) COVID-19 vaccinations and the development of haematopoietic cancers.

Censorship in science

Only relentless determination gets dissenting data published in peer-reviewed journals

Case Study

Healthy, young, athletic woman who,

developed acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL),

following her second dose of the Pfizer/BioNTech COVID-19 vaccine (Comirnaty®), (July 2021)

Drugs and Total Body Irradiation (TBI)

April, 2025, cell transplant from an unrelated donor.

Part of an expanding body of literature documenting similar occurrences after modRNA vaccinations.

30 papers describe malignancies that developed in close temporal relationship

with modRNA COVID-19 vaccinations.

(Often just a few days)

with 28 focusing on haemato-lymphoproliferative disorders.

In lymphoma, 4 cases, four cases showed onset at the inoculation site, three cases manifested in draining lymph nodes

Japan, leukaemia, breast, pancreatic, and lip/oral/ pharyngeal cancers increased significantly in 2022

critical literature gap: the absence of population studies verifying cancer incidence by vaccination status in order to estimate the true cancer incidence or mortality increases following COVID-19 vaccination.

‘technically pro-drug gene therapies encased in lipid

nanoparticles (LNPs), rather than natural naked mRNA.

Emerging evidence suggests that the biodistribution and persistence of modRNA, facilitated by lipid nanoparticles, can affect various tissues and organs,

including the bone marrow and other blood-forming organs.

Unfettered access through most tissues and organs,

Notably, modRNA vaccines exhibit a particular affinity for the bone marrow,

potentially influencing the immune system at multiple levels and,

triggering both autoimmune disorders and neoplastic processes.

By integrating clinical observations and current research,

we aim to provide valuable insights into the potential carcinogenic outcomes associated with modRNA vaccination.

Cancer causing Mechanisms

Toxic spike protein

Vaccine induced lasts for longer than natural spike

A double proline that confers greater stability.

Synthetic pseudouridines contained in the modRNA have shown mitochondrial toxicity

It has been demonstrated that this modification can

increase the likelihood of +1 ribosomal frameshifting

during translation,

resulting in the production of multiple peptide products with unexplored effects

(This obviously poses serious safety concerns as only a single antigen was supposed to be encoded by the modRNA, not many undefined peptides with unknown antigenic and autoimmune potential.)

LNPs exhibits intrinsic cytotoxicity.

Presence of LNP-encapsulated DNA contamination originating from residual plasmid DNA

DNA integration may include the risk of tumorigenisis if

insertion reduces the activity of a tumour suppressor

or increases the activity of an oncogene.

Vaccine induced T-cell immunosuppression, impairing cancer surveillance

Interaction between the S2 subunit of the spike protein and the oncosuppressor proteins p53, BRCA1, and BRCA2

The impairment in type I interferon (IFN) signalling

Increased Transforming Growth Factor Beta

(TGF-β) Production.

Vaccine begins to accumulate rapidly, particularly in the bone marrow,

between 30 minutes and 48 hours following intramuscular injection,

the concentration of radioactively labelled nanoparticles in the femoral bone marrow of rats increased by 7.9-fold.

Proposed vaccine-induced activation of innate immune

Pathways which induce proinflammatory cytokine production (e.g., IL-6).

This cytokine milieu activates the STAT3 pathway, which

promotes malignant T-cell proliferation, survival, and resistance to apoptosis in T-cell lymphoma.

Repeated vaccination may exacerbate overexpression and T-cell exhaustion,

impairing immune surveillance and enabling tumour

growth.

Repeated booster doses, correlating with increased levels of the immunosuppressive subtype immunoglobulin G4,

increasing immunosuppression and immune evasion.